Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-008826
Filing Date
2025-01-31
Accepted
2025-01-31 16:02:15
Documents
2
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0229351-6k_nlspharma.htm 6-K 21437
2 AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, DATED JANUARY 30, 2025, AMONG NLS ea022935101ex99-1_nls.htm EX-99.1 20273
  Complete submission text file 0001213900-25-008826.txt   42753
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 25578313
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)